Lincoln Pharmaceuticals Ltd (IN:LINCOLN)
:LINCOLN
Want to see IN:LINCOLN full AI Analyst Report?
Total Valuation
Lincoln Pharmaceuticals Ltd has a market cap or net worth of ₹12.28B. The enterprise value is ₹12.33B.
Market Cap₹12.28B
Enterprise Value₹12.33B
Share Statistics
Lincoln Pharmaceuticals Ltd has 20,029,728 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,029,728
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Lincoln Pharmaceuticals Ltd’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.07%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)8.07%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee3.98M
Profits Per Employee521.01K
Employee Count1,687
Asset Turnover0.75
Inventory Turnover5.63
Valuation Ratios
The current PE Ratio of Lincoln Pharmaceuticals Ltd is 13.9. Lincoln Pharmaceuticals Ltd’s PEG ratio is 1.91.
PE Ratio13.9
PS Ratio1.69
PB Ratio1.49
Price to Fair Value1.49
Price to FCF13.88
Price to Operating Cash Flow24.71
PEG Ratio1.91
Income Statement
In the last 12 months, Lincoln Pharmaceuticals Ltd had revenue of 6.71B and earned 878.94M in profits. Earnings per share was 43.88.
Revenue6.71B
Gross Profit2.20B
Operating Income831.84M
Pretax Income1.16B
Net Income878.94M
EBITDA976.84M
Earnings Per Share (EPS)43.88
Cash Flow
In the last 12 months, operating cash flow was 497.63M and capital expenditures -107.61M, giving a free cash flow of 390.02M billion.
Operating Cash Flow497.63M
Free Cash Flow390.02M
Free Cash Flow per Share19.47
Dividends & Yields
Lincoln Pharmaceuticals Ltd pays an annual dividend of ₹1.8, resulting in a dividend yield of 0.37%
Dividend Per Share₹1.8
Dividend Yield0.37%
Payout Ratio4.51%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.08
52-Week Price Change10.24%
50-Day Moving Average642.11
200-Day Moving Average560.52
Relative Strength Index (RSI)42.78
Average Volume (3m)1.66K
Important Dates
Lincoln Pharmaceuticals Ltd upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateMay 28, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Lincoln Pharmaceuticals Ltd as a current ratio of 5.25, with Debt / Equity ratio of 0.58%
Current Ratio5.25
Quick Ratio4.53
Debt to Market Cap<0.01
Net Debt to EBITDA-0.29
Interest Coverage Ratio82.12
Taxes
In the past 12 months, Lincoln Pharmaceuticals Ltd has paid 277.31M in taxes.
Income Tax277.31M
Effective Tax Rate0.24
Enterprise Valuation
Lincoln Pharmaceuticals Ltd EV to EBITDA ratio is 11.30, with an EV/FCF ratio of 13.54.
EV to Sales1.64
EV to EBITDA11.30
EV to Free Cash Flow13.54
EV to Operating Cash Flow10.32
Balance Sheet
Lincoln Pharmaceuticals Ltd has ₹2.32B in cash and marketable securities with ₹668.00K in debt, giving a net cash position of ₹2.32B billion.
Cash & Marketable Securities₹2.32B
Total Debt₹668.00K
Net Cash₹2.32B
Net Cash Per Share₹115.75
Tangible Book Value Per Share₹377.79
Margins
Gross margin is 38.06%, with operating margin of 12.40%, and net profit margin of 13.10%.
Gross Margin38.06%
Operating Margin12.40%
Pretax Margin17.23%
Net Profit Margin13.10%
EBITDA Margin14.56%
EBIT Margin12.40%
Analyst Forecast
The average price target for Lincoln Pharmaceuticals Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast7.67%
EPS Growth Forecast6.74%